Q1 EPS Forecast for Sarepta Therapeutics Reduced by Analyst

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Research analysts at Zacks Research lowered their Q1 2025 earnings estimates for shares of Sarepta Therapeutics in a research report issued to clients and investors on Monday, May 5th. Zacks Research analyst S. Ganoria now expects that the biotechnology company will earn ($2.70) per share for the quarter, down from their previous forecast of $1.56. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $2.67 per share. Zacks Research also issued estimates for Sarepta Therapeutics’ FY2025 earnings at $3.55 EPS.

SRPT has been the subject of a number of other research reports. Morgan Stanley reduced their price target on Sarepta Therapeutics from $196.00 to $182.00 and set an “overweight” rating for the company in a research report on Friday, April 11th. Wells Fargo & Company initiated coverage on Sarepta Therapeutics in a research report on Friday, April 11th. They set an “overweight” rating and a $115.00 target price for the company. Royal Bank of Canada lowered shares of Sarepta Therapeutics from an “outperform” rating to a “sector perform” rating and dropped their price target for the company from $161.00 to $87.00 in a research report on Monday, March 31st. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $163.00 price objective on shares of Sarepta Therapeutics in a report on Tuesday, March 18th. Finally, Scotiabank lowered their target price on shares of Sarepta Therapeutics from $105.00 to $80.00 and set a “sector perform” rating on the stock in a research note on Thursday, March 20th. Six research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $157.95.

Sarepta Therapeutics Stock Down 26.6 %

SRPT stock opened at $46.75 on Wednesday. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The firm has a market cap of $4.59 billion, a PE ratio of 37.40 and a beta of 0.85. Sarepta Therapeutics has a 1 year low of $36.79 and a 1 year high of $173.25. The company has a fifty day simple moving average of $70.87 and a 200 day simple moving average of $102.57.

Institutional Investors Weigh In On Sarepta Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. Manchester Capital Management LLC raised its holdings in shares of Sarepta Therapeutics by 86.6% in the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock worth $29,000 after buying an additional 110 shares in the last quarter. MassMutual Private Wealth & Trust FSB raised its stake in Sarepta Therapeutics by 169.6% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 156 shares in the last quarter. Byrne Asset Management LLC bought a new position in shares of Sarepta Therapeutics during the first quarter valued at $30,000. Center for Financial Planning Inc. acquired a new stake in shares of Sarepta Therapeutics in the 1st quarter valued at $31,000. Finally, Newbridge Financial Services Group Inc. bought a new stake in shares of Sarepta Therapeutics in the 4th quarter worth about $36,000. 86.68% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director Claude Nicaise sold 2,491 shares of the firm’s stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total transaction of $248,203.24. Following the completion of the transaction, the director now directly owns 27,812 shares of the company’s stock, valued at approximately $2,771,187.68. This trade represents a 8.22 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 7.70% of the stock is owned by company insiders.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.